COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM

被引：0
|
作者：
Fievez, S. [1 ]
Blanc, E. [1 ]
Bougeois, M. [1 ]
Sivignon, M. [2 ]
Supiot, R. [3 ]
Vietri, J. [4 ]
Perdrizet, J. [4 ]
Bellier, L. [3 ]
机构：
[1] Pfizer SAS France, Paris, France
[2] Putnam PHMR, Lyon, France
[3] Putnam PHMR, Paris, France
[4] Pfizer Inc, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL
    Jiang, Y.
    Yang, X.
    Petigara, T.
    Chabrol Haas, L.
    Graham, J.
    VALUE IN HEALTH, 2017, 20 (09) : A930 - A930
  • [2] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [3] COST-EFFECTIVENESS OF SWITCHING FROM PCV13 TO PCV20 IN THE PORTUGUESE CHILDHOOD NATIONAL IMMUNIZATION PROGRAM
    Mota, C.
    Ta, A.
    Vinand, E.
    Teixeira, R.
    Ilic, A.
    Perdrizet, J.
    VALUE IN HEALTH, 2024, 27 (12)
  • [4] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [5] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN BRAZIL
    Fujii, R. K.
    Mould, J. F.
    Presa, J.
    Jardim, E.
    Sato, R.
    Strutton, D. R.
    VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
  • [6] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [7] COST-EFFECTIVENESS ANALYSIS OF REPLACING PCV13 WITH PCV15 IN THE PEDIATRIC NATIONAL IMMUNIZATION PROGRAM OF GREECE
    Gountas, I
    Yfantopoulos, N.
    Trimis, G.
    Boutselakou, E.
    Poughias, L.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S136 - S137
  • [8] Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
    Dunne, Eileen M.
    Cilloniz, Catia
    von Mollendorf, Claire
    Lewnard, Joseph
    Grant, Lindsay R.
    Slack, Mary P. E.
    Jodar, Luis
    Theilacker, Christian
    Gessner, Bradford D.
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (03): : 157 - 164
  • [9] THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A427 - A427
  • [10] Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study
    Galina L. Ignatova
    Sergey N. Avdeev
    Vladimir N. Antonov
    Scientific Reports, 11
12345